Export
Model List of Essential Medicines
clear
Found 48 recommendations for 17 medicines and 4 therapeutic equivalents
Removed recommendations and rejected applications are shown. Hide them.
-
Atezolizumab General information
SectionImmunomodulators- Parenteral > General injections > IV: 1.2 g per 20 mL concentrate solution for infusion
- Parenteral > General injections > IV: 840 mg per 14 mL in vial concentrate for solution for infusion; 1200 mg per 20 mL in vial concentrate for solution for infusion
IndicationsOther specified malignant neoplasms of bronchus or lung Therapeutic equivalent to pembrolizumab for Other specified malignant neoplasms of bronchus or lung Therapeutic equivalent to pembrolizumab for Adenocarcinoma of stomach Hepatocellular carcinoma of liver -
Bevacizumab General information
SectionImmunomodulators- Parenteral > General injections > IV: 25 mg per mL in 4 mL vial concentrate for solution for infusion; 25 mg per mL in 16 mL vial concentrate for solution for infusion
Indications -
Blinatumomab General information
SectionImmunomodulators- Parenteral > General injections > IV: 35 µg in vial; 38.5 µg in vial
-
Cemiplimab General information
SectionImmunomodulators- Parenteral > General injections > IV: 50 mg per mL in 7 mL vial concentrate for solution for infusion
IndicationsTherapeutic equivalent to pembrolizumab for Other specified malignant neoplasms of bronchus or lung Therapeutic equivalent to pembrolizumab for Adenocarcinoma of stomach Other specified malignant neoplasms of bronchus or lung -
Daratumumab General information
SectionImmunomodulators- Parenteral > General injections > IV: 100 mg per 5 mL; 400 mg per 20 mL
Indications -
Dostarlimab General information
SectionImmunomodulators- Parenteral > General injections > IV: 50 mg per mL in 10 mL vial concentrate for solution for infusion
-
Durvalumab General information
SectionImmunomodulators- Parenteral > General injections > IV: 50 mg per mL in 2.4 mL vial concentrate solution for infusion; 50 mg per mL in 10 mL vial concentrate solution for infusion
-
Filgrastim General information
SectionImmunomodulators- Parenteral > General injections > SC: 120 µg per 0.2 mL in prefilled syringe; 300 µg per 0.5 mL in prefilled syringe; 480 µg per 0.8 mL in prefilled syringe; 300 µg per mL in 1 mL vial; 480 µg per 1.6 mL in 1.6 mL vial
Indications -
Ipilimumab General information
SectionImmunomodulators- Parenteral > General injections > IV: 5 mg per mL in 10 mL vial concentrate for solution for infusion; 20 mg per mL in 40 mL vial concentrate for solution for infusion
-
Lenalidomide General information
SectionImmunomodulators- Oral > Solid: 25 mg
Indications -
Nivolumab General information
SectionImmunomodulators- Parenteral > General injections > IV: 10 mg per mL concentrate solution for infusion
- Parenteral > General injections > IV: 10 mg per mL in 4 mL vial concentrate solution for infusion; 10 mg per mL in 10 mL vial concentrate solution for infusion; 10 mg per mL in 12 mL vial concentrate solution for infusion; 10 mg per mL in 24 mL vial concentrate solution for infusion
- Parenteral > General injections > IV: 10 mg per mL in 24 mL vial concentrate solution for infusion; 10 mg per mL in 4 mL vial concentrate solution for infusion; 10 mg per mL in 10 mL vial concentrate solution for infusion; 10 mg per mL in 12 mL vial concentrate solution for infusion
Indications -
Pegfilgrastim General information
SectionImmunomodulators- Parenteral > General injections > SC: 6 mg per 0.6 mL in pre-filled syringe
Indications -
Pembrolizumab General information
SectionImmunomodulators- Parenteral > General injections > IV: 25 mg per mL in 4 mL vial
- Parenteral > General injections > IV: 25 mg per mL in 4 mL vial powder for injection
- Parenteral > General injections > IV: 25 mg per mL in 4 mL vial concentrate for solution for infusion
IndicationsMelanoma of skin Malignant neoplasms of cervix uteri Other specified malignant neoplasms of large intestine Other specified malignant neoplasms of bronchus or lung Adenocarcinoma of stomach Squamous cell carcinoma of hypopharynx and variants Squamous cell carcinoma of other or ill-defined sites in the lip, oral cavity or pharynx Squamous cell carcinoma of oropharynx Squamous cell carcinoma of nasopharynx Malignant neoplasms of oesophagogastric junction Renal cell carcinoma of kidney, except renal pelvis Carcinoma of breast, specialised type Squamous cell carcinoma of oesophagus Therapeutic equivalent to nivolumab for Melanoma of skin -
Thalidomide General information
SectionImmunomodulators- Oral > Solid: 50 mg
Indications -
Tislelizumab General information
SectionImmunomodulators- Parenteral > General injections > IV: 100 mg per 10 mL
- Parenteral > General injections > IV: 100 mg per 10 mL contentrate for solution for infusion
- Parenteral > General injections > IV: 100 mg per 10 mL concentrate for solution for infusion
-
Toripalimab General information
SectionImmunomodulators- Parenteral > General injections > IV: 240 mg per 6 mL in vial
-
Tremelimumab General information
SectionImmunomodulators- Parenteral > General injections > IV: 20 mg per mL in 1.25 mL vial concentrate solution for infusion; 20 mg per mL in 15 mL vial concentrate solution for infusion